Masimo Co. (NASDAQ:MASI) Shares Sold by Alyeska Investment Group L.P.

Alyeska Investment Group L.P. lessened its position in shares of Masimo Co. (NASDAQ:MASI - Free Report) by 22.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 578,635 shares of the medical equipment provider's stock after selling 166,492 shares during the period. Alyeska Investment Group L.P. owned 1.08% of Masimo worth $95,648,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Jones Financial Companies Lllp purchased a new position in shares of Masimo in the fourth quarter worth about $27,000. UMB Bank n.a. grew its stake in Masimo by 180.9% in the 4th quarter. UMB Bank n.a. now owns 191 shares of the medical equipment provider's stock valued at $32,000 after buying an additional 123 shares in the last quarter. Trust Co. of Vermont bought a new stake in Masimo during the 4th quarter valued at $33,000. Blue Trust Inc. lifted its position in shares of Masimo by 56.3% during the fourth quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider's stock worth $33,000 after acquiring an additional 71 shares in the last quarter. Finally, EverSource Wealth Advisors LLC boosted its holdings in shares of Masimo by 40.0% in the fourth quarter. EverSource Wealth Advisors LLC now owns 224 shares of the medical equipment provider's stock worth $37,000 after acquiring an additional 64 shares during the period. Institutional investors own 85.96% of the company's stock.

Masimo Stock Down 0.9 %

Shares of Masimo stock traded down $1.39 during midday trading on Tuesday, hitting $161.47. The company had a trading volume of 902,363 shares, compared to its average volume of 662,715. Masimo Co. has a 52-week low of $101.61 and a 52-week high of $194.88. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.11 and a current ratio of 2.01. The company has a 50 day moving average of $164.19 and a 200 day moving average of $166.57. The stock has a market capitalization of $8.73 billion, a P/E ratio of 111.36 and a beta of 1.23.

Masimo (NASDAQ:MASI - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The medical equipment provider reported $1.36 earnings per share for the quarter, beating the consensus estimate of $1.24 by $0.12. Masimo had a return on equity of 14.98% and a net margin of 3.85%. During the same quarter in the previous year, the business posted $0.77 EPS. Masimo's revenue was down 24.5% compared to the same quarter last year. On average, equities analysts predict that Masimo Co. will post 4.1 earnings per share for the current fiscal year.

Insider Buying and Selling at Masimo

In other news, Director Craig B. Reynolds sold 2,053 shares of the stock in a transaction that occurred on Friday, March 14th. The stock was sold at an average price of $166.13, for a total transaction of $341,064.89. Following the completion of the transaction, the director now directly owns 16,581 shares in the company, valued at approximately $2,754,601.53. This represents a 11.02 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Bilal Muhsin sold 30,000 shares of Masimo stock in a transaction on Monday, March 10th. The stock was sold at an average price of $167.49, for a total transaction of $5,024,700.00. Following the completion of the transaction, the chief operating officer now directly owns 24,172 shares of the company's stock, valued at $4,048,568.28. The trade was a 55.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 9.70% of the company's stock.

Wall Street Analyst Weigh In

MASI has been the topic of several analyst reports. Wells Fargo & Company upped their price target on Masimo from $193.00 to $205.00 and gave the company an "overweight" rating in a research report on Wednesday, February 26th. Needham & Company LLC reiterated a "hold" rating on shares of Masimo in a research note on Thursday, April 10th. Finally, Piper Sandler raised their price target on shares of Masimo from $210.00 to $215.00 and gave the company an "overweight" rating in a report on Wednesday, February 26th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $194.80.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.